LONG-LASTING BLEED PROTECTIONFOR THE WORKHORSE WITHIN

#1 FACTOR IX MOST PRESCRIBED FOR PROPHYLAXIS*

ONLY IDELVION DELIVERS

Zero median annualized spontaneous bleeding rate in adults when dosed at 7 or 14 days in phase III pivotal trials

EXPLORE IDELVION
EFFICACY

Individualized dosing schedule that meets your patients' needs

VIEW FULL
DOSING INFORMATION

High and sustained Factor IX levels in clinical trials

DISCOVER HIGH FACTOR IX LEVELS

*In patients 12 years and older on a weekly dose of ≤40 IU/kg for 1 month while not requiring dose adjustments or experiencing spontaneous bleeding.

†The mean dose for patients receiving prophylaxis every 7 days was 37 IU/kg.

Request to Speak
With a Representative

Join us for a live webcast event!

Join us for an engaging discussion with a leading hematologist about the treatment of hemophilia B, an actual patient case study, and a clinical overview of IDELVION.

REGISTER NOW

June 9
12 PM EST
With Dr. Shveta Gupta

June 22
12 PM EST
With Dr. Vinod Balasa

July 28
12:00 PM EST
With Dr. Mark Reding

Print the enrollment form

So your patients can see if it’s right for them

DOWNLOAD FORM

Recommended for mobile devices

Resources for your patients

CSL Behring is committed to providing treatments and support services that make a meaningful difference in the lives of people with bleeding disorders.

Resources are available to help your patients get the treatment they need for hemophilia B, including:

A free trial of IDELVION
Co-pay assistance for eligible patients for up to $12,000 of annual out-of-pocket expenses
Lapse-in-coverage support with the CSL Behring Assurance^SM program
Reimbursement and access support

LEARN MORE ABOUT THE RESOURCES AVAILABLE FOR YOUR PATIENTS

References: 1. Hemophilia FIX Market Assessment, Third-Party Market Research. 2. Gill JC, Roberts J, Li Y, Castaman G. Sustained high trough factor IX activity levels with continued use of rIX-FP in adult and paediatric patients with haemophilia B. Haemophilia. 2019. doi:10.1111/hae.13735.